Breast cancer drug approved for NHS use after price cut

A drug that can help shrink breast cancer tumours before patients undergo surgery to remove them has been approved for use in the NHS, after the manufacturer agreed a substantial discount on the list price.

Perjeta, the brand name of pertuzumab, could be helpful in the treatment of 1,400 women a year who develop a particularly aggressive form of breast cancer, but it was initially turned down by Nice, the National Institute for Healthcare Excellence, because of the high price set by the manufacturer, Roche.

Nice said it was also uncertain that the drug treatment would help prevent the cancer coming back.

Prof Carole Longson, director of the centre for health technology assessment at Nice, said there was only limited evidence of how well the drug worked because it had been quickly licensed on the back of promising but early trial data.

She said Nice was glad Roche had agreed to drop the price, though she would not reveal by how much.

“The price discount means that, even with the uncertainties in the evidence highlighted by the committee, pertuzumab represents a cost-effective use of NHS money,” Longson said.

The list price of pertuzumab is £2,395 per 420mg vial (excluding VAT). The total cost of four cycles of treatment with pertuzumab – the maximum Nice says should be used – would be £9,580 before the agreed discount.

The drug is used in combination with two others, trastuzumab (Herceptin) and docetaxel (a type of chemotherapy), to shrink tumours prior to surgery. If it works well, it may mean some tumours that were previously inoperable could be surgically removed.

Pertuzumab has been developed to help treat the 10-15% of breast cancers that are HER2-positive, which can be particularly aggressive.

Nice pointed out that the decision was the third green light for a cancer drug in as many weeks. It has been criticised for failing to approve cancer drugs, which often come on to the market at high prices.

Mia Rosenblatt, assistant director of policy and campaigns at Breast Cancer Now, said it was a huge leap forward. “Perjeta is the first addition to primary breast cancer treatment to be approved by Nice since 2006 and marks the introduction of a new type of breast cancer medicine, to be used before surgery,” she said.

“For the small number of women eligible, this drug could mean an enormous amount. It could help shrink their tumours to reduce the extent of the surgery they require or even make inoperable cancers operable.”

Samia al-Qadhi, the chief executive of Breast Cancer Care, said: “This is an exciting turning point. Women with certain aggressive types of breast cancer will have access to an extra drug before surgery that can boost the success of shrinking the tumour. Crucially this may mean people’s long-term survival improves.”

Breast cancer drug approved for NHS use after price cut

Very first ever drug for Duchenne muscular dystrophy approved

There are around a hundred boys born with Duchenne muscular dystrophy every single year and there are two,400 living with it at present.

Patients with the condition lack regular dystrophin, a protein discovered in muscles. Due to the fact this protein aids to shield muscle tissues from injury as muscle tissue contract and unwind, in patients with the condition the muscle tissue grow to be damaged and eventually cease doing work.

In ten per cent to 15 per cent of instances, the condition is caused by specific mutations in their genes, named nonsense mutations.

Nonsense mutations in the dystrophin gene prematurely cease the manufacturing of a standard dystrophin protein, foremost to a shortened dystrophin protein that does not function properly.

Translarna is considered to perform in these patients by enabling the protein-generating apparatus in cells to skip over the defect, making it possible for the cells to make a functional dystrophin protein.

The European Medicines Agency had initially turned down Translarna due to a lack of evidence.

Nonetheless soon after representations, it reconsidered the drug, which includes a new examination of data submitted by the producer PTC Therapeutics.

It has now been given a conditional licence which enables early accessibility to medicines for daily life threatening conditions.

Robert Meadowcroft, chief executive of the Muscular Dystrophy Campaign, mentioned: “This selection by the EMA is wonderful information.

“There are 200 or more young children and young people in the United kingdom who reside with Duchenne muscular dystrophy triggered by a ‘nonsense mutation’, for whom Translarna has been made – ten to 15 per cent of the total variety affected by the issue.

“Every of them could now have independent entry to the drug without having needing to be portion of a clinical trial.

“Encouragingly, extending the numbers of individuals taking Translarna beyond individuals on PTC’s ultimate planned clinical trial will also aid to more accelerate improvement of the drug.

“Recent setbacks involving other prospective treatments for Duchenne muscular dystrophy have been disappointing for absolutely everyone racing against the clock to develop treatments that could shield muscle tissues from more damage.

“Duchenne muscular dystrophy leads to muscle groups to increasingly weaken and waste. Most of these diagnosed, generally before the age of 5, will use a powered wheelchair prior to they are twelve, will not have the muscle strength to pick up a glass of water by the age of twenty and will not dwell to see their 30th birthday. This stage forward for Translarna gives significantly needed hope.

“This is a substantial milestone in the search for remedies for Duchenne muscular dystrophy. There are two,400 children and youthful men and women residing with this complicated condition, and the Muscular Dystrophy Campaign is committed to funding a varied, peer-reviewed and ambitious analysis programme until effective therapies have been identified for every single single one of them.”

“We nowadays get in touch with for urgent meetings with the Nationwide Institute of Wellness of Clinical Excellence (Nice) and NHS England, to go over following steps to clear the path for their approval of Translarna and to make confident the drug reaches these for whom it could be effective without delay.”

Dr Craig McDonald, Professor of Bodily Medication and Rehabilitation at the University of California, Davis, explained: “This is a historic day for the Duchenne muscular dystrophy local community.

“Translarna is the first remedy for the underlying trigger of nonsense mutation DMD to acquire a positive opinion from the Committee for Medicinal Items for Human Use.”

Filippo Buccella, member of the United Mother or father Undertaking Muscular Dystrophy, explained: “After thirty many years because the discovery of the dystrophin gene, we are lastly starting to see a alter in the landscape.

“For the very first time in the history of Duchenne, we see the path to approval for a drug to treat the underlying lead to of DMD.

“The perseverance of this local community manufactured it attainable to realise a dream that can give hope to the boys affected.

“Our perform as a local community of sufferers is not however completed and we will stand ready to participate with PTC in the ensuing phases of this approach and, we hope, with a lot of other businesses with new therapies for Duchenne.”

Very first ever drug for Duchenne muscular dystrophy approved

NHS adds new cancer drugs to approved list

Two thousand more cancer patients a year will be able to access potentially life-extending treatments after the NHS added three more drugs to those available through the Cancer Drugs Fund.

Breast cancer campaigners said that women gaining access to trastuzumab emtansine through the £200m-a-year fund’s list of approved drugs in England was “a huge step forward”.

Dr Caitlin Palframan, senior policy manager at Breakthrough Breast Cancer, said the drug “has been shown to extend life by up to six months in HER2-positive secondary breast cancer patients, and with more manageable side-effects than alternative drugs. It has the potential to provide women with a better quality of life in their final months than existing treatments, which could make a significant difference.”

NHS England estimated that 1,100 women a year would gain access to the drug, 500-1,000 men to the prostate cancer drug Radium-223 dichloride, and about 70-120 people to dabrafenib, which is for patients with unrectable or metastatic skin cancers.

The Cancer Drugs Fund was introduced by the coalition in 2011 after an outcry over the National Institute for Health and Care Excellence denying cancer sufferers access to some expensive new medications it believed did not represent value for money. The fund has led to 38,000 people receiving drugs since then.

Prof Peter Clark, chair of NHS England’s chemotherapy clinical reference group, said: “These new additions to the list demonstrate NHS England’s commitment to achieving maximum benefit to patients from the annual £200m Cancer Drugs Fund.”

NHS adds new cancer drugs to approved list